282734-63-8Relevant articles and documents
ESTROGEN RECEPTOR ANTAGONIST
-
, (2021/10/07)
Provided is an indole compound. In particular, disclosed are a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof and a use of the same as an estrogen receptor antagonist in preparing a drug for treating estrogen receptor-positive breast cancer.
Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors
Baltus, Christine B.,Jorda, Radek,Marot, Christophe,Berka, Karel,Bazgier, Václav,Kry?tof, Vladimír,Prié, Gildas,Viaud-Massuard, Marie-Claude
, p. 701 - 719 (2016/01/09)
From four molecules, inspired by the structural features of fascaplysin, with an interesting potential to inhibit cyclin-dependent kinases (CDKs), we designed a new series of tri-heterocyclic derivatives based on 1H-pyrrolo[2,3-b]pyridine (7-azaindole) an
A convenient iodination of indoles and derivatives
Hamri, Salha,Rodríguez, Jose,Basset, Joan,Guillaumet, Gérald,Dolors Pujol
supporting information; experimental part, p. 6269 - 6275 (2012/08/28)
We report a direct iodination of indole and derivative compounds with iodine monochloride (ICl) in the presence of Celite. This procedure has now been extended to the iodination of substituted indoles, azaindoles and pyrroles. The scope of this procedure